Mosapride

DB11675InvestigationalSmall molecule

Mosapride is a prokinetic 5-HT4 receptor agonist used to stimulate gastric motility. Mosapride is under investigation for the treatment and prevention of Postoperative Ileus and Gastric Peroral Endoscopic Pyloromyotomy (G-POEM).

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 4
Curator reviewed
Formula / weight: C₂₁H₂₅ClFN₃O₃ · 421.9 g/mol (avg)

Resolves to

Compound

UNIII8MFJ1C0BYCAS112885-41-3ChEMBLCHEMBL60889ChEBI167204PubChem119584

Clinical / RWD

RxNorm135091ATCA03FA09

Structure

InChIKeyYPELFRMCRYSPKZ-UHFFFAOYSA-NSMILESCCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1CN(CC2=CC=C(F)C=C2)CCO1

Targets

Q13639HTR4

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

707Drug interactionsStructured to mechanism, not free text

36Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

4ContraindicationsEach with its own population and attribute set

19Marketed productsAcross 2 countries and 10 labellers

1ATC codeIncluding every combination product, plus 16 drug categories

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mosapride, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account